Skip to content

Study · Non-randomized trial · 2009

5 results

Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment.

Watts NB, Miller PD, Kohlmeier LA, Sebba A, Chen P, Wong M, Krohn K

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Jun 2009Cited by 23 (Europe PMC)

PMID19113918 (opens in a new tab)DOI10.1359/jbmr.081256 (opens in a new tab)PepBankPUB-19113918
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In postmenopausal women, femoral neck BMD losses above 4% occurred less often with teriparatide than placebo.

    In plain wordsIn postmenopausal women, substantial femoral neck bone density loss occurred less often with teriparatide than placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseFemoral neck BMD loss above threshold
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Women with FN BMD loss >4%
    10%
    teriparatide
    Women with FN BMD loss >4%
    16%
    placebo

    Source sentences

    Summary
    Decreases of >4% FN BMD were less common in women receiving TPTD (10%) versus PL (16%, p < 0.05), yet women on TPTD who lost FN BMD still had significant reductions in VF risk compared with PL (RR = 0.11; 95% CI = 0.03-0.45).
    1 context sentence
    Summary · context
    We examined vertebral fracture (VF) risk, change in lumbar spine (LS) BMD, and change in amino-terminal extension peptide of procollagen type I (PINP) in postmenopausal women whose femoral neck (FN) BMD decreased, increased, or was unchanged after receiving teriparatide (TPTD) or placebo (PL) in the…
  2. 02HumanNon-randomized trialEfficacy outcome

    In postmenopausal women, teriparatide increased lumbar spine BMD versus placebo regardless of femoral neck BMD response.

    In plain wordsIn postmenopausal women, teriparatide increased lower spine bone density versus placebo regardless of femoral neck bone density response.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Irrespective of FN BMD loss or gain, TPTD-treated women had statistically significant increases in LS BMD and PINP compared with PL.
    1 context sentence
    Summary · context
    We examined vertebral fracture (VF) risk, change in lumbar spine (LS) BMD, and change in amino-terminal extension peptide of procollagen type I (PINP) in postmenopausal women whose femoral neck (FN) BMD decreased, increased, or was unchanged after receiving teriparatide (TPTD) or placebo (PL) in the…
  3. 03HumanNon-randomized trialActivity measurement

    In postmenopausal women, teriparatide increased PINP versus placebo regardless of femoral neck BMD response.

    In plain wordsIn postmenopausal women, teriparatide increased a bone formation marker versus placebo regardless of femoral neck bone density response.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePINP
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Irrespective of FN BMD loss or gain, TPTD-treated women had statistically significant increases in LS BMD and PINP compared with PL.
    1 context sentence
    Summary · context
    We examined vertebral fracture (VF) risk, change in lumbar spine (LS) BMD, and change in amino-terminal extension peptide of procollagen type I (PINP) in postmenopausal women whose femoral neck (FN) BMD decreased, increased, or was unchanged after receiving teriparatide (TPTD) or placebo (PL) in the…
  4. 04HumanObservational studyEfficacy outcome

    In women who lost femoral neck BMD, teriparatide reduced vertebral fracture risk versus placebo.

    In plain wordsIn women who lost femoral neck bone density, teriparatide reduced spine fracture risk versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseVertebral fracture risk with femoral neck BMD loss
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    RR
    0.11 ratio
    teriparatide versus placebo

    Source sentences

    Summary
    Decreases of >4% FN BMD were less common in women receiving TPTD (10%) versus PL (16%, p < 0.05), yet women on TPTD who lost FN BMD still had significant reductions in VF risk compared with PL (RR = 0.11; 95% CI = 0.03-0.45).
    1 context sentence
    Summary · context
    We examined vertebral fracture (VF) risk, change in lumbar spine (LS) BMD, and change in amino-terminal extension peptide of procollagen type I (PINP) in postmenopausal women whose femoral neck (FN) BMD decreased, increased, or was unchanged after receiving teriparatide (TPTD) or placebo (PL) in the…

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 05HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome

    In postmenopausal women, teriparatide's vertebral fracture risk reduction versus placebo was similar across femoral neck BMD response categories.

    In plain wordsIn postmenopausal women, teriparatide reduced spine fracture risk versus placebo similarly across femoral neck bone density response categories.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeFracture risk reduction across femoral neck BMD response categories
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    VF risk reduction with TPTD compared with PL was similar across categories of FN BMD change from baseline at 12 mo (loss >4%, loss 0-4%, gain 0-4%, or gain >4%; interaction p = 0.40).
    1 context sentence
    Summary · context
    We examined vertebral fracture (VF) risk, change in lumbar spine (LS) BMD, and change in amino-terminal extension peptide of procollagen type I (PINP) in postmenopausal women whose femoral neck (FN) BMD decreased, increased, or was unchanged after receiving teriparatide (TPTD) or placebo (PL) in the…

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.